Insmed Incorporated (NASDAQ:INSM) faces a challenging landscape with a ROIC of -46.16%, indicating substantial inefficiencies in capital utilization.

• The company’s negative ROIC sharply contrasts its WACC of 10.76%, raising concerns for potential investors.
• Comparatively, Amicus Therapeutics shows a more favorable ROIC at 7.53%, offering a glimpse of potential recovery.
• Halozyme Therapeutics leads with an impressive ROIC of 22.84%, suggesting efficient capital management.

This analysis reflects the significant challenges Insmed faces in generating returns above its cost of capital, making it crucial for management to implement effective strategies for improvement.